Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; Mereo BioPharma Shares Spike Higher

Toward the end of trading Friday, the Dow traded down 0.71% to 30,088.36 while the NASDAQ fell 0.40% to 12,714.00. The S&P also fell, dropping 0.77% to 3,693.85.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 17,213,880 cases with around 310,790 deaths. India confirmed a total of at least 9,979,440 confirmed cases and 144,780 deaths, while Brazil reported over 7,110,430 COVID-19 cases with 184,820 deaths. In total, there were at least 75,075,060 cases of COVID-19 worldwide with over 1,664,760 deaths, according to data compiled by Johns Hopkins University.

Leading and Lagging Sectors

Materials shares slipped by just by 0.02% on Friday. Meanwhile, top gainers in the sector included US Concrete Inc USCR, up 8%, and Amyris Inc AMRS, up 6%.

In trading on Friday, energy shares dipped 2%.

Top Headline

Darden Restaurants, Inc. DRI reported stronger-than-expected earnings for its second quarter.

Darden posted quarterly earnings of $0.74 per share, beating analysts’ estimates of $0.71 per share. The company’s quarterly sales came in at $1.66 billion, versus expectations of $1.68 billion.


Equities Trading UP

Exela Technologies, Inc. XELA shares shot up 27% to $0.4597. Exela Technologies secured a term loan of $145 million.

Shares of CURO Group Holdings Corp CURO got a boost, shooting 79% to $15.75. Katapult will go public through merger with FinServ Acquisition Corp. Katapult is 40% owned by CURO Group.

Mereo BioPharma Group plc MREO shares were also up, gaining 57% to $3.46. Mereo BioPharma and Ultragenyx announced a license and collaboration agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta.

Equities Trading DOWN

Mesoblast Limited MESO shares tumbled 34% to $8.92. Mesoblast said Data Safety Monitoring Board that performed a third interim analysis of data from a study of remestemcel-L in ventilator-dependent patients with moderate to severe acute respiratory distress syndrome due to COVID-19 infection said the trial is not likely to meet the 30-day mortality reduction endpoint at the planned 300 patient enrolment.

Shares of Scopus BioPharma Inc. SCPS were down 40% to $20.27 after climbing 474% on Thursday. Scopus BioPharma’s filing showed registration for 500,000 share common stock offering. Scopus Biopharma priced its IPO at $5.5 per share.

Applied DNA Sciences, Inc. APDN was down, falling 16% to $5.24 after the company reported downbeat quarterly results.


In commodity news, oil traded up 1.5% to $49.06, while gold traded down 0.2% to $1,886.10.

Silver traded down 0.7% Friday to $26.00 while copper rose 0.9% to $3.6335.

Euro zone

European shares closed lower today. The eurozone’s STOXX 600 fell 0.35%, the Spanish Ibex Index fell 1.42%, while Italy’s FTSE MIB Index declined 0.16%. Meanwhile, the German DAX 30 slipped 0.27%, French CAC 40 declined 0.39% and London’s FTSE 100 fell 0.33%.

German producer prices dropped 0.5% year-over-year in November following a 0.7% decline in the previous month, while retail sales in the UK dropped 3.8% in November.


The current account gap increased by 10.6% to $178.5 billion in the third quarter.

The index of leading economic indicators rose 0.6% for November.

The total number of active U.S. oil rigs rose by 5 to 263 rigs this week, Baker Hughes Inc reported.

Posted In: Mid-Afternoon Market UpdateEarningsNewsPenny StocksEurozoneCommoditiesSmall CapGlobalIntraday UpdateMarkets

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.